far. Indeed the half-life of ALA synthetase in rat liver has been estimated to be about 70 min (Marver et al. 1966 ). However, my colleague, Dr J Marriott, has recently carried out some experiments on the stability of the microbial enzyme. This preparation of ALA synthetase loses its activity very quickly when incubated at 370C by itself and none of the ordinary agents used for stabilizing proteins has much effect on this loss. However, the addition of glycine and succinate and pyridoxal phosphate in various combinations (the substrates of this enzyme) bring about a very marked increase in stability (Table 1 ).
It seems likely that one mechanism of control may be the following: Some enzymes which are only required intermittently may have a very short life and their inactivation or degradation may be a specific process. However, stability can be increased by the presence of certain low molecular substances which are also substrates of the enzyme. In this manner a regulation is exercised by the presence of substrate which greatly increases the stability of an enzyme which otherwise would be quickly inactivated. If such a mechanism were to operate in the biosynthesis of porphyrin the cause of increased ALA synthetase activity in porphyria may not be that of inactivation or repression but may be due to a different mechanism such as reduced rate of formation of repressor or inhibitor or increase of the life of the enzyme by stabilization. In this work so far we have assumed that the increase in ALA synthesis is characteristic for acute intermittent porphyria. Dowdle et al. (1967) have recently carried out some comparative investigations on the ALA synthetase of liver samples obtained by biopsy. They have found that the increase is in no way confined to acute intermittent porphyria and a similar rise is also observed in variegate porphyria and in symptomatic porphyria. In other words this increase in enzyme activity cannot be a specific cause of acute intermittent porphyria. This seems very likely since none of the substances involved, such as ALA or PBG, has been shown to have any toxic action. In other inheritable diseases with a known metabolic basis, such as galactosaemia or phenylketonuria, the intermediates of metabolism which accumulate in excessive amounts are toxic, but reduction to normal levels by appropriate therapy can eliminate or ameliorate toxic effects. It is unlikely that lowering of the concentrations of ALA and PBG in plasma or cells would affect the basic disease process in acute intermittent porphyria. It is thus probable that increased production of ALA and PBG is only one expression of a widespread disturbance of cellular metabolism or of subcellular organization, the nature of which is still unknown. REFERENCES Bogorad L (1965) 
Diagnosis and Treatment ofthe Porphyrias
We can divide the porphyrias at present into two main types, hepatic and erythropoietic (Table 1) . This classification is based on the main site of formation of the abnormal porphyrins and their precursors. Under the hepatic heading we can include acute intermittent porphyria, the variegate type of porphyria, which occurs commonly in South Africa in those of Dutch extraction and also the cutaneous hepatic porphyrias be they hereditary in origin or acquired. Attention has now also been drawn to a distinct type of porphyria called hereditary coproporphyria , which is also hepatic in type. Of these hepatic types only acute intermittent porphyria never presents with cutaneous manifesta-tions. Variegate porphyria very often does, the cutaneous hepatic type usually does and hereditary coproporphyria occasionally presents with cutaneous manifestations in addition to acute manifestations. Of the two main types of erythropoietic porphyria the one which has been most recently described, erythropoietic protoporphyria, is much more common than the excessively rare congenital porphyria. These erythropoietic types of porphyria only present with cutaneous manifestations.
Hepatic Porphyrias Acute intermittent porphyria: There are three ways in which the acute type of porphyria may present:
(1) Unexplained abdominal pains quite often associated with vomiting and constipation and occasionally with diarrhcea. (2) Unexplained paresis or paralysis usually peripheral in type, but sometimes with an upper neurone lesion. (3) Unexplained psychiatric manifestations mimicking any of the psychoses or psychoneuroses. There may be other less common presenting features such as epilepsy. These are the three main groups of presenting symptoms which should alert one to the possibility that a porphyria of the acute type is present.
Acute intermittent porphyria may have several courses. It may be latent and only picked up when examining the excreta of relatives. It may consist of short attacks of intermittent abdominal pain or an explosive type of attack ending fatally or there may be several severe attacks which usually peter out within a decade or there may be a course of ascending severity ending fatally. The disease most commonly occurs in women in the third decade of life but may present in males, or in early childhood and in old age. It is transmitted as a mendelian dominant character, which is a point of considerable importance in diagnosis. Because of its relative rarity and the protean nature of its symptoms, the diagnosis may be elusive. Acute intermittent porphyria has a remarkable similarity in its presenting clinical and biochemical features to lead poisoning (Dagg et al. 1965 ). The diagnosis is established by finding excess excretion of porphobilinogen and 8-amino lkvulic acid in the ;urine.
Cutaneous hepatic porphyria: In the cutaneous hepatic type of porphyria there is often evidence of hepatic insufficiency with mild jaundice and abnormal empirical liver function tests. This is a type of disease which used to be called porphyria cutanea tarda and when it presents for the first time in middle age or in the elderly it is unlikely to be associated with acute manifestations.
When cutaneous hepatic porphyria presents in the adolescent or young adult it may be associated with acute manifestations. Such a mixed type of porphyria occurs commonly in South Africa, and has been termed 'porphyria variegata' in which either acute manifestations or photosensitivity may occur together in the same individual or separately in different individuals of the same family. In the cutaneous porphyrias, the excess porphyrins may be excreted both in urine and faces. Where there is impaired hepatic function the main excretion route is urinary. Excess urinary excretion of porphobilinogen and 8-amino levulic acid occurs when acute symptoms are superimposed.
Hereditary coproporphyria has now been defined as a distinct type of porphyria which may be provoked by drugs into attacks resembling those of acute intermittent porphyria. It is a unique biochemical disorder, a separate type of porphyria in which the abnormality occurs in the liver. Although there may be a transient excess excretion of porphobilinogen and 8-amino lkvulic acid in attacks, the only chemical abnormality in states of remission may be the increased excretion of coproporphyrin III in the fmeces. The genetic transmission in most patients up till now has been of the dominant type although there has been one family in which it has been recessive. Most of the cases, and 30 have been described, present with acute manifestations but there has been one example of cutaneous manifestations.
Erythropoietic Porphyrias
Erythropoietic protoporphyria presents with skin photosensitivity in the first few years of life and the diagnosis may only be made by examining the blood for excess protoporphyrin. Fecal porphyrins are sometimes increased but urinary porphyrins are always normal.
Congenital porphyria usually presents from birth. It is excessively rare and the clinical features are those of gross photosensitization and pink teeth. The diagnosis can always be made by examination of the urine for formed porphyrins.
Diagnosis
In practice porphyria presents in two main ways, as an acute disease with abdominal pain and the other manifestations that we have considered and as a photosensitizing disease of the skin, the cutaneous type. In the acute presentation it is essential to examine the urine for 8-amino levulic acid, porphobilinogen and excess coproporphyrin. The feces must also be examined for excess coproporphyrin and protoporphyrin because in both porphyria variegata (mixed porphyria) and hereditary coproporphyria there are excessive porphyrins in the faces.
When the cutaneous manifestations of porphyria present for the first time the diagnosis must be confirmed by examination of the urine for uroporphyrin, coproporphyrin, 5-amino lkvulic acid and porphobilinogen, of the feces for coproporphyrin and protoporphyrin and of the blood for protoporphyrin and coproporphyrin. In the type of cutaneous porphyria which is provoked by alcohol and other hepatotoxic substances the urine contains excessive quantities of porphyrins. In other types of cutaneous hepatic porphyria, such as porphyria variegata the facal poiphyrins wili always be raised. Examination of the blood porphyrins may be the only way of diagnosing erythropoietic protoporphyria.
Treatment
Prevention: There is still no rational method for a fundamental approach to the treatment of the porphyrias. Much, however, can be done in the way of prevention and management of these diseases and the mortality has been considerably reduced in the past thirty years. Patients with acute intermittent porphyria in remission should avoid precipitating factors such as any of the barbiturates and other drugs mentioned below. Infections and alcoholic excess are important provoking factors. No dogmatic statement can be made concerning the effect of pregnancy in acute porphyria. In some cases pregnancy may be completed with impunity and in others it may gravely and sometimes fatally overtax the patient. The danger does not stop at labour for the early part of the puerperium is treacherous. Ifadvice is asked on pregnancy the dangers must be explained and if it occurs the obstetrician should be warned. When any surgical procedure becomes necessary a barbiturate must not be used in anesthesia. The contraceptive pill must also never be used because of its cestrogen content.
Management ofthe acute attack: During the acute attack patients are often difficult to nurse and treat. Their constant request for analgesia may even give a false impression that they are drug addicts. The patient is best treated in a side-ward rather than a general ward. For relief of pain, pethidine or morphine is usually necessary. Physeptone and aspirin are not contraindicated but are usually too weak as analgesics. When convulsions occur intramuscular paraldehyde is the drug of choice. Promazine orally in a dose of 25-50 mg three or four times daily is an effective remedy for the pain and nervous and psychological symptoms during an acute attack. It has no effect on the excretion of porphyrins or porphyrin precursors or established paralysis. In the presence of acute psychotic symptoms a single intramuscular injection of 100-200 mg of promazine should be given. In the presence of paralysis or paresis the limbs should be correctly maintained in positions of function and physiotherapy should be started as soon as possible and continued until maximal recovery has been attained. The treatment of fluid imbalance is important. Hypochloriemia and hyponatremia quite often complicate an acute attack. This is often associated with excessive vomiting and inadequate fluid intake and in these cases adequate fluid and salt replacement and, where there is hypotension, corticotrophin (ACTH) 100-200 units per day should be given. There is now evidence that the cause of the hyponatr;mia in some cases is an inapprepriate secretion of antidiuretic hormone giving rise to a low serum sodium and serum osmolality, high urine osmolality and diminished water clearance, a state which is treated by water restriction alone. Nielsen & Thorn (1965) have demonstrated a transient excess in the urinary excretion of antidiuretic hormone in acute porphyria. Where there is significant hypertension, hypotensive drugs can be used with the exception of methyldopa which has been found to aggravate the disease in some cases.
Contraindicated drugs: The drugs which are contraindicated in the porphyrias are barbiturates, the sulphonamides, (estrogens, the contraceptive pill, chloroquine, griseofulvin and possibly dichloralphenazone (Welldorm) and methyldopa.
Respiration: Any patient with an acute attack may develop respiratory paralysis. Modern methods of artificial respiration with tracheostomy and intermittent positive pressure have saved lives. A progressive weakening of the voice is an important premonitory sign of impending respiratory failure. The physician should have no hesitation in enlisting the assistance of a respiiatory unit for this purpose. A complete recovery has been obtained in patients who have been several months on intermittent positive pressure.
Diet: There is evidence that the porphyric state may be aggravated by withdrawal of protein and carbohydrate and the author has seen a severe attack precipitated in a girl who placed herself on a very strict weight-reducing diet. The role of the diet in experimental human porphyria has been emphasized by Welland et al. (1964) . In patients with latent porphyria urinary porphobilinogen excretion is decreased by giving an increased carbohydrate and protein diet. The patient suffering an acute attack may not be able to take a high carbohydrate, high protein diet and the author has made preliminary observations on the use of concentrated lkvulose intravenously in a severe attack. Four pints of 20 % 1kevulose were given intravenously. Between each bottle half a pint of normal saline was given I.V. to avoid thrombosis of the vein. There was clinical improvement and a fall in the urinary 8-amino levulic acid, porphobilinogen and urinary uroporphyrin in 2 instances. Renal hemodialysis has been used in a few cases of acute intermittent porphyria (Rees et al. 1967) . There is in fact no real evidence that there is a circulating toxic factor present in the blood which causes symptoms; the porphyrins themselves and their precursors are nontoxic. It is more likely that the clinical manifestations are caused by some underlying biochemical disorder, associated with the hepatic defect in the acute types of porphyria. In one patient with porphyria variegata who was in coma the dialysis was followed by a significant fall in the level of 8-amino levulic acid, porphobilinogen and uroporphyrin, and marked improvement of the clinical state.
Summary
There is still no rational method for a fundamental approach to the treatment of the porphyrias, but a great deal has been done already in lowering the mortality rate. Death in the past has been caused by respiratory failure and terminal bronchopneumonia and the use of tracheostomy and intermittent positive pressure techniques and chemotherapy has undoubtedly been responsible for the diminution of mortality. The two most important points in the management of acute porphyria are rapid diagnosis for those affected and the detection of latent porphyria among their families. Although qualitative tests for the detection of porphyrins and the precursors in the urine and stool are helpful it is now recognized that quantitative studies are necessary to define clearly the latent case (Lancet 1967 One of the more powerful tools in photobiology is so-called 'action spectroscopy', the relating of biological response to wavelength and dose of radiation. It is important because it is based on a fundamental principle of photochemistry, the Grotthus-Draper law. This states that wavelengths that are absorbed will activate a substance susceptible to photochemical change; those wavelengths that are not absorbed will not activate it.
To forecast what wavelengths should be reactive, we need to know the absorption spectrum of the photosensitizer, where its identity is known. Where the photosensitizer is not known, one hopes to recognize it from comparing the results of action spectroscopy with the absorption spectra of known substances.
In action spectroscopy of the skin one relates the activity of a skin response to the wavelength and dose of the radiation; the result is called an 'action spectrum'. This sort of work started with the pioneer studies of Hausser & Vable (1921) in Germany on the sunburn response in normal skin. Human skin is very reactive to shorter ultraviolet wavelengths and a polykymatic emitter, e.g. mercury arc, of modest power is here sufficient as a source for a small irradiation monochromator. The action spectrum shows that the most effective wavelength in terrestrial sunlight for sunburn is at about 300 nm; wavelengths longer than about 320 nm, however, had very little erythemal action.
The study of the action spectrum of the skin of patients with porphyria is, however, recent. Before this explanations of the mechanism of the photosensitivity associated with these diseases were controversial and mostly unsatisfactory. It is ironical to note, however, that the photobiological mechanism underlying porphyria in sheep was well understood. But the position over human porphyria changed with the ready commercial availability of the high pressure xenon arc about ten years ago.
Using this arc, a number of high-intensity irradiation monochromators have been developed at the Institute of Dermatology, London, and elsewhere, especially in the USA.
Patients with porphyria who may be clinically photosensitive include those with hepatic cutaneous porphyria, variegate porphyria and the rare congenital porphyria, but not acute intermittent
